J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC

​J&J has received the US FDA approval for a new monthly dosing schedule for the combination therapy Rybrevant Faspro to treat patients with advanced, EGFR-mutated NSCLC.

The post J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.